• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    11/16/22 8:08:12 AM ET
    $AIRS
    $ALZN
    $ANIP
    $APTX
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIRS alert in real time by email

    Gainers

    • ANI Pharmaceuticals (NASDAQ:ANIP) shares rose 31.1% to $47.99 during Wednesday's pre-market session. The market value of their outstanding shares is at $837.6 million.
    • Sunshine Biopharma (NASDAQ:SBFM) stock increased by 19.48% to $1.0. The company's market cap stands at $22.5 million.
    • Spruce Biosciences (NASDAQ:SPRB) stock increased by 17.14% to $1.23. The company's market cap stands at $28.9 million. As per the news, the Q3 earnings report came out 4 days ago.
    • Statera BioPharma (NASDAQ:STAB) stock increased by 16.86% to $0.14. The company's market cap stands at $7.4 million.
    • Burning Rock Biotech (NASDAQ:BNR) shares increased by 10.52% to $2.52. The market value of their outstanding shares is at $266.4 million. As per the news, the Q3 earnings report came out yesterday.
    • AirSculpt Technologies (NASDAQ:AIRS) stock moved upwards by 9.71% to $3.39. The market value of their outstanding shares is at $190.4 million. The company's, Q3 earnings came out 4 days ago.

    Losers

    • Aptinyx (NASDAQ:APTX) stock declined by 34.9% to $0.21 during Wednesday's pre-market session. The company's market cap stands at $14.4 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares declined by 19.56% to $0.23. The market value of their outstanding shares is at $7.5 million.
    • Trevena (NASDAQ:TRVN) stock fell 16.19% to $2.9. The market value of their outstanding shares is at $20.1 million.
    • Lucira Health (NASDAQ:LHDX) shares fell 12.63% to $0.38. The market value of their outstanding shares is at $15.2 million. As per the press release, Q3 earnings came out 2 days ago.
    • Alzamend Neuro (NASDAQ:ALZN) shares declined by 12.13% to $0.98. The market value of their outstanding shares is at $93.9 million.
    • BrainsWay (NASDAQ:BWAY) shares declined by 10.32% to $2.87. The company's market cap stands at $47.4 million. As per the news, the Q3 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRS
    $ALZN
    $ANIP
    $APTX

    CompanyDatePrice TargetRatingAnalyst
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    Spruce Biosciences Inc.
    $SPRB
    10/28/2025$254.00Mkt Perform → Mkt Outperform
    Citizens JMP
    ANI Pharmaceuticals Inc.
    $ANIP
    7/10/2025$84.00Buy
    H.C. Wainwright
    ANI Pharmaceuticals Inc.
    $ANIP
    3/14/2025$80.00Buy
    Jefferies
    ANI Pharmaceuticals Inc.
    $ANIP
    3/12/2025$85.00Overweight
    Analyst
    Spruce Biosciences Inc.
    $SPRB
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    Spruce Biosciences Inc.
    $SPRB
    12/11/2024Outperform → Perform
    Oppenheimer
    More analyst ratings

    $AIRS
    $ALZN
    $ANIP
    $APTX
    SEC Filings

    View All

    SEC Form 6-K filed by BrainsWay Ltd.

    6-K - Brainsway Ltd. (0001505065) (Filer)

    3/19/26 7:30:05 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by BrainsWay Ltd.

    6-K - Brainsway Ltd. (0001505065) (Filer)

    3/17/26 4:01:07 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form NT 10-K filed by AirSculpt Technologies Inc.

    NT 10-K - Airsculpt Technologies, Inc. (0001870940) (Filer)

    3/16/26 6:54:56 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    $ALZN
    $ANIP
    $APTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Deng Feng

    3 - Burning Rock Biotech Ltd (0001792267) (Issuer)

    3/18/26 8:17:50 PM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Wadman Brent R

    3 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/18/26 7:22:03 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Zangen Abraham

    3 - Brainsway Ltd. (0001505065) (Issuer)

    3/18/26 4:05:51 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $AIRS
    $ALZN
    $ANIP
    $APTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health

    BURLINGTON, Mass. and JERUSALEM, March 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has completed a $1 million milestone-based investment in Axis Management Company, Inc. ("Axis Integrated Mental Health" or "Axis"), a management services organization servicing several mental health clinics in Colorado. The investment was made following Axis's achievement of a predefined revenue performance milestone under the terms of the two companies' August 2025 strategic equity financing agreement. "We are excited for the Axis tea

    3/19/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

    Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patientsTopline data expected in third quarter of 2026Topline data from the clinically completed "lithium in brain" imaging study in healthy subjects expected by the end of March 2026ATLANTA, March 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the initi

    3/16/26 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AirSculpt Technologies Announces Its Intent to Delay the Filing of its Annual Report and Provides Business Update

    Preliminary Fiscal Year 2025 Revenue of $151.8 Million Refreshed Marketing Strategy Delivers Positive Same-Store Sales in February 2026 Strong Balance Sheet and Enhanced Liquidity MIAMI BEACH, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced that it expects to file a Form 12b-25 with the U.S. Securities and Exchange Commission (the "SEC") on or about March 16, 2026, providing the Company a 15-day extension to file its annual report for the fiscal year ended December 31, 2025 on Form 10-K (the "Annual Report"). The extension will give the Company a

    3/16/26 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    $ALZN
    $ANIP
    $APTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Spruce Biosciences with a new price target

    Oppenheimer initiated coverage of Spruce Biosciences with a rating of Outperform and set a new price target of $283.00

    12/23/25 8:47:57 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Spruce Biosciences from Market Perform to Outperform and set a new price target of $160.00

    12/3/25 8:26:32 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Spruce Biosciences from Mkt Perform to Mkt Outperform and set a new price target of $254.00

    10/28/25 8:00:24 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIRS
    $ALZN
    $ANIP
    $APTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $257,211 worth of shares (105,848 units at $2.43), increasing direct ownership by 2% to 6,592,059 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/16/26 6:43:51 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $91,200 worth of shares (45,600 units at $2.00), increasing direct ownership by 0.72% to 6,398,211 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/9/26 8:40:24 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $192,900 worth of shares (110,000 units at $1.75), increasing direct ownership by 2% to 6,352,611 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/4/26 6:58:41 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    $ALZN
    $ANIP
    $APTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

    Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

    3/8/21 5:11:24 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXYCODONE AND ASPIRIN

    Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

    3/8/21 5:11:06 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for EZETIMIBE AND SIMVASTATIN

    Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

    2/25/21 5:09:42 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIRS
    $ALZN
    $ANIP
    $APTX
    Leadership Updates

    Live Leadership Updates

    View All

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

    Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible

    3/9/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Burning Rock Announces Results of 2025 Annual General Meeting

    GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to d

    12/22/25 11:04:44 PM ET
    $BNR
    Medical Specialities
    Health Care

    $AIRS
    $ALZN
    $ANIP
    $APTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

    SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    11/14/24 5:45:17 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevena Inc.

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    11/14/24 4:43:11 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

    SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    11/14/24 4:39:47 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIRS
    $ALZN
    $ANIP
    $APTX
    Financials

    Live finance-specific insights

    View All

    BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage  Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million Remaining Performance Obligations Increased 43% to Approximately $70 Million Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth) Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIR

    3/11/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

    Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1) Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectivelyRecord quarterly and full year adjusted non-GAAP EBIT

    2/27/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

    BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, March 11, 2026Time:8:30 AM Eastern TimeUnited States:1-877-300-8521Internationa

    2/25/26 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care